[Colorectal cancer in ulcerative colitis].

Area of Science:

• Gastroenterology
• Oncology
• Inflammatory Bowel Disease

Context:

• Ulcerative colitis (UC) is an inflammatory bowel disease associated with an increased risk of colorectal cancer (CRC).
• Previous estimates of CRC risk in UC patients may have been overestimated.
• The efficacy of chemoprevention strategies in this population remains uncertain.

Purpose:

• To review the current evidence regarding colorectal cancer (CRC) risk in patients with ulcerative colitis (UC).
• To evaluate the effectiveness of chemoprevention in UC-associated CRC.
• To provide updated recommendations for surveillance strategies in UC patients.

Summary:

• The actual risk of developing colorectal cancer (CRC) in individuals with ulcerative colitis (UC) appears to be lower than previously reported.
• Chemoprevention has not demonstrated proven efficacy in reducing CRC risk within the UC population.
• Surveillance for CRC in UC patients should be concentrated in specialized centers and focus on high-risk subgroups, including those with extensive disease, early onset, dysplasia, or primary sclerosing cholangitis.

Impact:

• Refines understanding of CRC risk in UC, potentially reducing unnecessary anxiety and interventions for lower-risk patients.
• Highlights the need for evidence-based surveillance, advocating for targeted approaches like chromoendoscopy over random biopsies.
• Informs clinical practice guidelines for managing UC patients, emphasizing personalized risk assessment and optimized screening protocols.